Study Sponsor: Teva Pharmaceuticals
Phase: Phase II, Safety and Efficacy
Clinical Sites in NC: None
The Pride-HD Study aims to enroll approximately 400 patients at 30 sites across the globe and evaluate the safety and efficacy of pridopidine. Pridopidine is an investigational, oral, small molecule being developed for the symptomatic treatment of Huntington’s disease
Qualifying patients for The Pride-HD study must be 21 years of age or older, with an onset of HD after age 18 and must have a diagnosis of HD based on clinical features.
The goal is to determine if it reduces chorea and increases functional ability. It is a dose-finding safety and tolerability study; some patients will be given a placebo. The drug has a different mechanism of action than Tetrabenazine (TBZ).
Contact Christine O’Neill at (336)716-8611 for more information about how to enroll and for eligibility requirements.